title: Efficacy of a vancomycin solution to prevent bacteremia associated with an indwelling central venous catheter in neutropenic and non-neutropenic cancer patients.
abstract: We evaluated the efficacy of a vancomycin solution in the prevention of bacteremia caused by vancomycin-sensitive organisms (VSO) in cancer patients with a tunneled central venous catheter (CVC). Eighty-three patients who had a single lumen CVC were randomized to use a heparin solution (25 U/ml) for daily catheter flush with (HepVan) or without (Hep) vancomycin, 25 mcg/ml. Febrile episodes were recorded, and central and peripheral blood cultures were drawn before beginning antibiotic therapy. Patients participated in follow-up to 16,677 catheter days (8,666 Hep and 8,011 HepVan), and 143 febrile episodes were recorded (82 Hep and 61 HepVan). Forty-four episodes of bacteremia occurred, 23 of them due to VSO (16 occurred in the Hep group and 7 in the HepVan group (P = 0.19). VSO bacteremia occurred in 14 neutropenic (absolute neutrophil count < 500 x 10(9)/l) episodes (7 Hep vs. 7 HepVan) and in 9 non-neutropenic episodes (9 Hep vs. O HepVan; P = 0.013). Vancomycin effectively prevented bacteremia by VSO in non-neutropenic patients, supporting the idea that intraluminal colonization of indwelling CVCs contributes to bacteremia only in these patients.
authors.affiliation: Department of Pediatrics, Pontificia Universidad Católica de Chile, Santiago, Chile.
authors.forename: F J
authors.initials: FJ
authors.lastname: Barriga
authors.forename: M
authors.initials: M
authors.lastname: Varas
authors.forename: M
authors.initials: M
authors.lastname: Potin
authors.forename: F
authors.initials: F
authors.lastname: Sapunar
authors.forename: H
authors.initials: H
authors.lastname: Rojo
authors.forename: A
authors.initials: A
authors.lastname: Martinez
authors.forename: V
authors.initials: V
authors.lastname: Capdeville
authors.forename: A
authors.initials: A
authors.lastname: Becker
authors.forename: P A
authors.initials: PA
authors.lastname: Vial
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000925:Anticoagulants / Q000008:administration & dosage; D016470:Bacteremia / Q000209:etiology / Q000382:microbiology / Q000517:prevention & control*; D002405:Catheterization, Central Venous / Q000009:adverse effects*; D002408:Catheters, Indwelling / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D005260:Female; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood* / Q000628:therapy; D009503:Neutropenia / Q000150:complications*; D011446:Prospective Studies; D014640:Vancomycin / Q000008:administration & dosage*
chemical_list: D000900:Anti-Bacterial Agents; D000925:Anticoagulants; D014640:Vancomycin; D006493:Heparin